DNA Sequencing for Endometrial Cancer

(OPTEC Trial)

Recruiting at8 trial locations

Overseen by Paul Goodfellow

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Ohio State University Comprehensive Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strategies. Universal tumor DNA sequencing may help doctors better understand how to personalize care, increase length of life, and increase quality of life in patients with endometrial cancer and their relatives.

Research Team

Paul Goodfellow

Principal Investigator

Ohio State University Comprehensive Cancer Center

Eligibility Criteria

This trial is for adult women diagnosed with endometrial adenocarcinoma who had a hysterectomy or biopsy between certain dates and were treated at participating hospitals. It's also for their relatives found to have Lynch Syndrome. Excluded are non-English speakers, those unable to consent, prisoners, pregnant women, and women with uterine sarcomas.

Inclusion Criteria

I had a hysterectomy or biopsy showing endometrial cancer between 10/1/2017 and 4/30/2020.

I am an adult relative of someone with Lynch syndrome.

Exclusion Criteria

I can make my own medical decisions.

Individuals must be able to speak and read English; non-English speaking individuals will be excluded

Prisoners will be specifically excluded from participation in the study

Treatment Details

Interventions

• Universal Endometrial Cancer DNA Sequencing (Genetic Testing)

Trial Overview The study is testing universal DNA sequencing on tumors from endometrial cancer patients to detect Lynch Syndrome and other genetic changes that could inform personalized treatment plans aimed at improving lifespan and quality of life.

Participant Groups

Group I: Comprehensive LS genetic testing Experimental Treatment 4 Interventions

Testing for inherited forms of cancer and tumor sequencing

Who Is Running the Clinical Trial?

Ohio State University Comprehensive Cancer Center

Lead Sponsor

Trials

350

Recruited

295,000+

Dr. David Cohn

Ohio State University Comprehensive Cancer Center

Interim Chief Executive Officer since 2022

MD, MBA

Dr. David Cohn

Ohio State University Comprehensive Cancer Center

Chief Medical Officer since 2018

MD

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School